Ocular manifestations of juvenile Paget disease

Archives of Ophthalmology

Volumn 128, Issue 6, 2010, Pages 698-703

  Kerr, Nathan M ^a   Cassinelli, Hamilton R ^b   DiMeglio, Linda A ^d   Tau, Cristina ^c   Tüysüz, Beyhan ^e   Cundy, Tim ^a   Vincent, Andrea L ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Hospital de Niños R Gutiérrez   (Argentina)

^c HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANGIOID STREAK; ARTICLE; ATROPHY; CLINICAL ARTICLE; DISEASE ASSOCIATION; EYE EXAMINATION; EYE FUNDUS; FEMALE; HUMAN; MALE; PAGET BONE DISEASE; PHENOTYPE; PIGMENT EPITHELIUM; PREVALENCE; PRIORITY JOURNAL; RETINA DISEASE; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; ANGIOID STREAKS; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OPTIC ATROPHY; OSTEITIS DEFORMANS; OSTEOPROTEGERIN; RETINAL PIGMENT EPITHELIUM; VISION DISORDERS; VISUAL ACUITY; YOUNG ADULT;

EID: 77953645267     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.76     Document Type: Article

References (30)

1. Whyte MP, Singhellakis PN, Petersen MB, Davies M, Totty WG, Mumm S. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966-969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J Bone Miner Res. 2007;22 (6):938-946.
2. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347(3):175-184.
3. Chong B, Hegde M, Fawkner M, et al; International Hyperphosphatasia Collaborative Group. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res. 2003;18(12): 2095-2104.
4. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002;11(18):2119-2127.
5. Whyte MP. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-κB signaling. Ann N Y Acad Sci. 2006;1068:143-164.
6. Bakwin H, Golden A, Fox S. Familial osteoctasia with macrocranium. Am J Roentgenol Radium Ther Nucl Med. 1964;91:609-617.
7. Iancu TC, Almagor G, Friedman E, Hardoff R, Front D. Chronic familial hyperphosphatasemia. Radiology. 1978;129(3):669-676.
8. Mitsudo SM. Chronic idiopathic hyperphosphatasia associated with pseudoxanthoma elasticum. J Bone Joint Surg Am. 1971;53(2):303-314.
9. Sharif KW, Doig WM, Kinsella FP. Visual impairment in a case of juvenile Paget's disease with pseudoxanthoma elasticum: an eleven-year follow-up. J Pediatr Ophthalmol Strabismus. 1989;26(6):299-302.
10. Bakwin H, Eiger MS. Fragile bones and macrocranium. J Pediatr. 1956;49(5):558-564.
11. Thompson RC Jr, Gaull GE, Horwitz SJ, Schenk RK. Hereditary hyperphosphatasia: studies of three siblings. Am J Med. 1969;47(2):209-219.
12. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22(4):549-553. (Pubitemid 34408732)
13. Luft FC. Pseudoxanthoma elasticum revealed. J Mol Med. 2000;78(5):237-238.
14. Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol. 1993;116 (4):414-423. (Pubitemid 23299485)
15. National Center for Biotechnology Information. Tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B). http://www.ncbi.nlm.nih.gov/ UniGene/clust.cgi?UGID=140556&TAXID=9606&SEARCH=osteoprotegerin. Accessed March 26, 2009.
16. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260-1268.
17. 3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem. 2000;275(28):20959-20962.
18. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363-14367.
19. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis. 2006;184(2):446-447. (Pubitemid 43049733)
20. McGonigle JS, Giachelli C, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009; 12(1):35-46.
21. 3 of bone-derived cells isolated from normal children and children with abnormalities in skeletal development. J Clin Endocrinol Metab. 1986; 62(3):583-590.
22. -/- mice. Arterioscler Thromb Vasc Biol. 2006;26(9):2117-2124.
23. Allen CA, Hart BL, Taylor CL, Clericuzio CL. Bilateral cavernous internal carotid aneurysms in a child with juvenile Paget disease and osteoprotegerin deficiency. AJNR Am J Neuroradiol. 2008;29(1):7-8.
24. Schievink WI. Intracranial aneurysms. N Engl J Med. 1997;336(1):28-40.
25. Cundy T, Wheadon L, King A. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res. 2004;19(5):703-711. (Pubitemid 41094379)
26. Tau C, Mautalen C, Casco C, Alvarez V, Rubinstein M. Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone. 2004;35(1):210-216. (Pubitemid 38789166)
27. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med. 2005;353(9):918-923. (Pubitemid 41247931)
28. Romas E. Clinical applications of RANK-ligand inhibition. Intern Med J. 2009;39 (2):110-116.
29. Puig J, Garcia-Arumi J, Salvador F, Sararols L, Calatayud M, Alforja S. Subretinal neovascularization and hemorrhages in angioid streaks [in Spanish]. Arch Soc Esp Oftalmol. 2001;76(5):309-314.
30. Lim JI. Iatrogenic choroidal neovascularization.SurvOphthalmol. 1999;44(2):95-111.